About Raynovich Rod
Rod Raynovich is an experienced biotech investor an analyst with a focus in vaccines, tools, IVD’s and biopharmaceuticals. Prior to starting Raygent, he was a former technology transfer officer for UCLA and he has held various executive positions in the biotech and pharmaceutical industry, including senior positions at NASDAQ listed medical device companies. He was a founder and […]
© Carlo Allegri/Reuters A trader works on the floor of the New York Stock Exchange on the last day of trading before Christmas in the Manhattan borough of New York, December 24, 2014.U.S. stocks fluctuated, with the Standard & Poor’s 500 Index (SPX) poised for a third straight yearly gain as equity gauges climbed past multiple milestones last week.Gilead […]
Few industries offer the promise and pitfalls of biotechnology. Clinical wins and losses can lead to extraordinary stock gains or falls that make the sector best suited for only the most risk-tolerant investor. However, for investors willing to take on that risk, our Motley Fool contributors believe these three biotech stocks could offer significant opportunities in the coming year.Brian Orelli […]
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk, low-growth biotech stocks that investors might consider avoiding: Inovio Pharmaceuticals , VIVUS , and Zogenix .Inovio Pharmaceuticals At first glance, […]
Source: Flickr user Mark EsauBargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over such companies, with many of them having little to no hope of ever reliving their glory days.Aegerion Pharmaceuticals , MannKind Corp. , and […]
My afternoon train reads:
• The Best Thing for Active Managers? Passive Investors. — As institutions slash active mandates, managers on both sides of the active versus passive argument rejoice. (Chief Investment Officer)• The Reformed Broker talks markets and investing (Vanguard)• The State of Consumer Technology at the End of 2014 (Stratechery)• What Life in Cuba Was Like After Castro’s Revolution (New Republic)• D.H. Robertson […]
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the S&P 500 , and more than doubled the NASDAQ Composite , since 2012.This sustained move upward, though, has repeatedly […]
Source: MercK & Co.,Just when it looked as though the stock market couldn’t possibly finish the year higher, after its swoon in October, it proved the naysayers wrong. As of this writing, the S&P 500 has risen by 11% for the year, a tad bit higher than the stock markets’ historic annual return.But if you think that’s a solid return, […]
It’s been an eventful and promising year for pharma. The eyeforpharma team choose their top five pharma news stories of 2014.Globally, healthcare is high on citizens’ and policy-makers’ agendas and, wherever healthcare and business intersect, we find controversy. Indeed, this year, pharma has hardly seemed to be out of the headlines, becoming part of the international news agenda on several […]
U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity.Major indexes opened slightly lower after data showed China’s exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan’s economy shrank more […]
